Finanzen von Oruka Therapeutics Inc (ORKA)ORKAOruka Therapeutics Inc

Evaluating the bottom line, Oruka Therapeutics, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -18.30%, provide a clear picture of how effectively ORKA converts its operational activities into shareholder value.

In the context of the broader market, ORKA competes directly with industry leaders such as RGC and ERAS. With a market capitalization of $5.24B, it holds a leading position in the sector. When comparing efficiency, ORKA's gross margin of N/A stands against RGC's N/A and ERAS's N/A. Such benchmarking helps identify whether Oruka Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Oruka has been experiencing significant losses, with net income reaching -41,206,000 USD in Q2 2026 and a negative EPS of -0.66. The current ratio is very high at 38.51, indicating strong liquidity.